Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.

PURPOSE To evaluate through a longitudinal study the effects on visual fields of long-term vigabatrin medication in patients with partial epilepsy and to discuss visual field screening strategies. METHODS A total of 26 patients aged 14-68 years with a mean history of vigabatrin medication of 8.5 years (range 2-14 years) were followed by manual kinetic Goldmann perimetry (objects IV,4 and I,4) for 6-26 months (mean value 12.3 months). At time zero and at follow-up, each patient was assigned a "pooled" averaged value, as a linear percentage of normal isopter position, for the two objects as tested nasally and temporally in the five most horizontal meridians on the Goldmann chart. Twelve eyes from nine adults (age 24-60 years) served as controls. RESULTS Constrictions were recorded in 24 of 26 patients at baseline. Averaged isopters ranged from 8% to 96% of the controls' averaged isopter positions. Median values of 71.5% and 60.5% for large and small objects, respectively, indicated that the smaller object was more sensitive to visual field constriction. There was no difference in the degree of constriction between nasal and temporal hemifields. Significant improvement in the visual field (mean gain 13.6% units) was seen in the eight patients who underwent full drug withdrawal. No similar improvement was seen in the 12 patients still on full dose or the six with reduced intake. CONCLUSIONS Most Danish patients on long-term vigabatrin medication have suffered some visual field loss. Contrary to most clinical evidence so far, the present follow-up study indicates some reversibility of visual field loss after drug withdrawal. Kinetic Goldmann perimetry appears to be a fair alternative to computerized static perimetry techniques for screening and following vigabatrin-treated patients.

[1]  E. Ben-Menachem,et al.  Vigabatrin Visual Toxicity: Evolution and Dose Dependence , 2001, Epilepsia.

[2]  M. Engelsman,et al.  Visual Field Loss Associated with Vigabatrin: Quantification and Relation to Dosage , 2001 .

[3]  E. Brodtkorb,et al.  Visual field defects in patients taking vigabatrin. , 2000, Acta ophthalmologica Scandinavica.

[4]  G. Harding,et al.  Separating the retinal electrophysiologic effects of vigabatrin , 2000, Neurology.

[5]  G. Krauss,et al.  Visual function loss from vigabatrin , 2000, Neurology.

[6]  C. V. van Veelen,et al.  Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin , 2000, The British journal of ophthalmology.

[7]  K. Krakow,et al.  Recovery of visual field constriction following discontinuation of vigabatrin1 1 Author to whom correspondence should be addressed; Dr. Karsten Krakow, MD, Neurologische Klinik, Klinikum der Goethe-Universitdt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany. E-mail: k.krakow@em.uni-frankfurt.de , 2000, Seizure.

[8]  S. Nightingale,et al.  A controlled study of vigabatrin and visual abnormalities , 2000, The British journal of ophthalmology.

[9]  G. Krauss,et al.  Visual dysfunction in patients receiving vigabatrin , 1999, Neurology.

[10]  G. Harding,et al.  Characteristics of a Unique Visual Field Defect Attributed to Vigabatrin , 1999, Epilepsia.

[11]  G. Harding,et al.  Visual field defects associated with vigabatrin therapy , 1999, Journal of neurology, neurosurgery, and psychiatry.

[12]  J. Partanen,et al.  Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects , 1999, Neurology.

[13]  P. Kertes,et al.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin. , 1999, Ophthalmology.

[14]  G. Krauss,et al.  Vigabatrin-associated retinal cone system dysfunction , 1998, Neurology.

[15]  T Eke,et al.  Retrospective study of concussive convulsions in elite Australian rules and rugby league footballers: phenomenology, aetiology, and outcome , 1997, BMJ.

[16]  D. Chadwick,et al.  Outcomes After Seizure Recurrence in People with Well‐Controlled Epilepsy and the Factors That Influence It , 1996, Epilepsia.

[17]  H. Høgenhaven,et al.  Vigabatrin in Childhood Epilepsy: A 5-Year Follow-Up Study , 1995, Neuropediatrics.